Ocumension Therapeutics was EyePoint’s largest product and service line in fiscal 2025, bringing in $1.00M of $1.60M (63%).
| Product and Service | FY 2011 | FY 2013 | FY 2015 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Alimera | — | — | — | — | ||||||
| Product Rights Agreement & The Supply Agreement | — | $2.10M | $2.60M | — | ||||||
| Ocumension Therapeutics | $400.00K | $600.00K | $600.00K | $1.00M | ||||||
| Swk | $900.00K | $1.00M | $1.10M | — | ||||||
| Ani Pharmaceuticals, Inc | — | $1.00M | $700.00K | $600.00K | ||||||
| Amended Alimera Agreement | — | — | — | — | ||||||
| Pfizer Collaboration Agreement | — | — | — | — | ||||||
| Feasibility Study Agreement | — | — | — | — | ||||||
| Enigma Therapeutics Limited | — | — | — | — | ||||||
| Oncosil Medical Uk Limited | — | — | — | — | ||||||
| Amended Alimera Science Inc Agreement | — | — | — | — | ||||||
| Intrinsiq | — | — | — | — | ||||||
| Total | $1.30M | $4.70M | $5.00M | $1.60M |
EyePoint brought in $1.60M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $20.43M it reports by product and service, so these lines do not cover all of its revenue. Ocumension Therapeutics was the largest at $1.00M (62.5%), ahead of Ani Pharmaceuticals, Inc at $600.00K (37.5%).
Compared with fiscal 2024, Ocumension Therapeutics grew 66.7% to $1.00M, while Ani Pharmaceuticals, Inc fell 14.3% to $600.00K. Some of that change comes from EyePoint regrouping its lines.
EyePoint began breaking out Ani Pharmaceuticals, Inc in fiscal 2023, when it brought in $1.00M. EyePoint stopped reporting Product Rights Agreement & The Supply Agreement ($2.60M in fiscal 2024) and Swk ($1.10M in fiscal 2024) as separate lines.
License & Collaboration Agreement was EyePoint’s largest product and service line in fiscal 2025, bringing in $16.83M of $20.43M (82%).
| Product and Service | FY 2016 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License & Collaboration Agreement | $562.00K | $100.00K | $800.00K | $16.83M | |||||||
| Product Sales, Net | — | $2.10M | $2.60M | $1.60M | |||||||
| Product | $400.00K | — | — | — | |||||||
| Yutiq | $343.00K | — | $3.10M | $1.60M | |||||||
| Rpa | $900.00K | — | $1.10M | — | |||||||
| Royalty Income | $1.44M | $989.00K | $500.00K | $400.00K | |||||||
| Collaborative Research & Development | — | — | — | — | |||||||
| Dexycu | $20.00K | — | — | — | |||||||
| Total | $3.66M | $3.19M | $8.10M | $20.43M |
EyePoint brought in $20.43M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. EyePoint regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $8.10M. License & Collaboration Agreement was the largest at $16.83M (82.4%), ahead of Yutiq at $1.60M (7.8%) and Product Sales, Net at $1.60M (7.8%). The remaining line, Royalty Income, brought in $400.00K.
Compared with fiscal 2024, License & Collaboration Agreement grew fastest, up 2,004.3% to $16.83M, while Yutiq fell the most, down 48.4% to $1.60M.
EyePoint began breaking out Product Sales, Net in fiscal 2023, when it brought in $2.10M. EyePoint stopped reporting Rpa ($1.10M in fiscal 2024), Product ($400.00K in fiscal 2022) and Dexycu ($20.00K in fiscal 2022) as separate lines.
China was EyePoint’s largest region in fiscal 2024, bringing in $1.12M of $1.22M (92%).
| Geography | FY 2011 | FY 2014 | FY 2018 | FY 2018 | FY 2022 | FY 2024 |
|---|---|---|---|---|---|---|
| Country Us | — | — | ||||
| U.S | — | — | ||||
| China | $823.00K | $1.12M | ||||
| United Kingdom | $100.00K | $100.00K | ||||
| U.K | — | — | ||||
| Total | $923.00K | $1.22M |
EyePoint brought in $1.22M from its two regions in fiscal 2024, the year ended December 31, 2024. That was up 32.6% from $923.00K in fiscal 2022, the previous year with figures. China was the largest at $1.12M (91.8%), ahead of United Kingdom at $100.00K (8.2%).
Compared with fiscal 2022, the previous year with figures, China grew 36.6% to $1.12M and United Kingdom grew 0.0% to $100.00K. From fiscal 2022 to 2024, combined revenue from these regions grew from $923.00K to $1.22M, a compound annual growth rate of 15.2%. China's share of the total rose from 89.2% to 91.8%.
EyePoint (EYPT) reports its revenue by product and service and by geography. In fiscal 2025, Ocumension Therapeutics was its largest product and service line, bringing in $1.00M (62.5% of the total), followed by Ani Pharmaceuticals, Inc at $600.00K (37.5%).
Ocumension Therapeutics was EyePoint's largest product and service line in fiscal 2025, bringing in $1.00M, or 62.5% of the $1.60M total across its two product and service lines.
China was EyePoint's largest region in fiscal 2024, bringing in $1.12M, or 91.8% of the $1.22M total across its two regions.
Every figure comes from EyePoint's annual financial filings, as reported. Each line keeps the name EyePoint gives it, and years follow its fiscal calendar.
EyePoint's revenue by product and service goes back to fiscal 2011, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.